Search

Your search keyword '"Arbizu, Javier"' showing total 366 results
Start Over Author "Arbizu, Javier"
366 results on '"Arbizu, Javier"'

1. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy

Author

Traub-Weidinger, Tatjana, Arbizu, Javier, Barthel, Henryk, Boellaard, Ronald, Borgwardt, Lise, Brendel, Matthias, Cecchin, Diego, Chassoux, Francine, Fraioli, Francesco, Garibotto, Valentina, Guedj, Eric, Hammers, Alexander, Law, Ian, Morbelli, Silvia, Tolboom, Nelleke, Van Weehaeghe, Donatienne, Verger, Antoine, Van Paesschen, Wim, von Oertzen, Tim J., Zucchetta, Pietro, and Semah, Franck

Published
2024
Full Text
View/download PDF

3. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study

Author

Mitjavila, Mercedes, Jimenez-Fonseca, Paula, Belló, Pilar, Pubul, Virginia, Percovich, Juan Carlos, Garcia-Burillo, Amparo, Hernando, Jorge, Arbizu, Javier, Rodeño, Emilia, Estorch, Montserrat, Llana, Belén, Castellón, Maribel, García-Cañamaque, Lina, Gajate, Pablo, Riesco, Maria Carmen, Miguel, Maria Begoña, Balaguer-Muñoz, David, Custodio, Ana, Cano, Juana María, Repetto, Alexandra, Garcia-Alonso, Pilar, Muros, Maria Angustias, Vercher-Conejero, Jose Luis, and Carmona-Bayonas, Alberto

Published
2023
Full Text
View/download PDF

18. Updated Appropriate Use Criteria for Amyloid and Tau PET

Author

Rabinovici, Gil D., primary, Knopman, David S., additional, Arbizu, Javier, additional, Benzinger, Tammie L.S., additional, Donohoe, Kevin, additional, Hansson, Oskar, additional, Herscovitch, Peter, additional, Kuo, Phillip, additional, Lingler, Jennifer H, additional, Minoshima, Satoshi, additional, Murray, Melissa E., additional, Price, Julie C, additional, Salloway, Stephen, additional, Weber, Christopher J., additional, Carrillo, Maria C., additional, and Johnson, Keith A., additional

Published
2023
Full Text
View/download PDF

19. The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

Author

Galldiks, Norbert, Law, Ian, Pope, Whitney B, Arbizu, Javier, and Langen, Karl-Josef

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Neurosciences, Brain Disorders, Cancer, Rare Diseases, Brain Cancer, Amino Acids, Brain Neoplasms, Dihydroxyphenylalanine, Humans, Methionine, Positron-Emission Tomography, Radiopharmaceuticals, Tyrosine, PET, FET, MET, FDOPA, Glioma, Temozolomide, Bevacizumab, Immunotherapy, Checkpoint inhibitors, Pseudoprogression, Pseudoresponse, Biological psychology, Clinical and health psychology
Abstract

Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers 11C-methyl-l-methionine (MET), O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.

Published
2017

20. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Author

Albert, Nathalie L, Weller, Michael, Suchorska, Bogdana, Galldiks, Norbert, Soffietti, Riccardo, Kim, Michelle M, la Fougère, Christian, Pope, Whitney, Law, Ian, Arbizu, Javier, Chamberlain, Marc C, Vogelbaum, Michael, Ellingson, Ben M, and Tonn, Joerg C

Subjects
Animals, Humans, Glioma, Brain Neoplasms, Radiopharmaceuticals, Positron-Emission Tomography, Molecular Imaging, PET imaging, amino acid PET, glioma, guideline, recommendations, Rare Diseases, Neurosciences, Brain Cancer, Cancer, Clinical Research, Brain Disorders, Biomedical Imaging, Orphan Drug, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

This guideline provides recommendations for the use of PET imaging in gliomas. The review examines established clinical benefit in glioma patients of PET using glucose ((18)F-FDG) and amino acid tracers ((11)C-MET, (18)F-FET, and (18)F-FDOPA). An increasing number of studies have been published on PET imaging in the setting of diagnosis, biopsy, and resection as well radiotherapy planning, treatment monitoring, and response assessment. Recommendations are based on evidence generated from studies which validated PET findings by histology or clinical course. This guideline emphasizes the clinical value of PET imaging with superiority of amino acid PET over glucose PET and provides a framework for the use of PET to assist in the management of patients with gliomas.

Published
2016

21. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

Author

Chételat, Gaël, Arbizu, Javier, Barthel, Henryk, Garibotto, Valentina, Law, Ian, Morbelli, Silvia, van de Giessen, Elsmarieke, Agosta, Federica, Barkhof, Frederik, Brooks, David J, Carrillo, Maria C, Dubois, Bruno, Fjell, Anders M, Frisoni, Giovanni B, Hansson, Oskar, Herholz, Karl, Hutton, Brian F, Jack, Clifford R, Jr, Lammertsma, Adriaan A, Landau, Susan M, Minoshima, Satoshi, Nobili, Flavio, Nordberg, Agneta, Ossenkoppele, Rik, Oyen, Wim J G, Perani, Daniela, Rabinovici, Gil D, Scheltens, Philip, Villemagne, Victor L, Zetterberg, Henrik, and Drzezga, Alexander

Published
2020
Full Text
View/download PDF

22. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

Author

Morbelli, Silvia, Esposito, Giuseppe, Arbizu, Javier, Barthel, Henryk, Boellaard, Ronald, Bohnen, Nico I., Brooks, David J, Darcourt, Jacques, Dickson, John C., Douglas, David, Drzezga, Alexander, Dubroff, Jacob, Ekmekcioglu, Ozgul, Garibotto, Valentina, Herscovitch, Peter, Kuo, Phillip, Lammertsma, Adriaan, Pappata, Sabina, Peñuelas, Iván, Seibyl, John, Semah, Franck, Tossici-Bolt, Livia, Van de Giessen, Elsmarieke, Van Laere, Koen, Varrone, Andrea, Wanner, Michele, Zubal, George, and Law, Ian

Published
2020
Full Text
View/download PDF

24. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

Author

Law, Ian, Albert, Nathalie L., Arbizu, Javier, Boellaard, Ronald, Drzezga, Alexander, Galldiks, Norbert, la Fougère, Christian, Langen, Karl-Josef, Lopci, Egesta, Lowe, Val, McConathy, Jonathan, Quick, Harald H., Sattler, Bernhard, Schuster, David M., Tonn, Jörg-Christian, and Weller, Michael

Published
2019
Full Text
View/download PDF

27. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia

Author

Bouwman, Femke, Orini, Stefania, Gandolfo, Federica, Altomare, Daniele, Festari, Cristina, Agosta, Federica, Arbizu, Javier, Drzezga, Alexander, Nestor, Peter, Nobili, Flavio, Walker, Zuzana, Morbelli, Silvia, Boccardi, Marina, and for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders

Published
2018
Full Text
View/download PDF

28. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease

Author

Drzezga, Alexander, Altomare, Daniele, Festari, Cristina, Arbizu, Javier, Orini, Stefania, Herholz, Karl, Nestor, Peter, Agosta, Federica, Bouwman, Femke, Nobili, Flavio, Walker, Zuzana, Frisoni, Giovanni Battista, Boccardi, Marina, and for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders

Published
2018
Full Text
View/download PDF

31. Clinical utility of FDG-PET for the clinical diagnosis in MCI

Author

Arbizu, Javier, Festari, Cristina, Altomare, Daniele, Walker, Zuzana, Bouwman, Femke, Rivolta, Jasmine, Orini, Stefania, Barthel, Henryk, Agosta, Federica, Drzezga, Alexander, Nestor, Peter, Boccardi, Marina, Frisoni, Giovanni Battista, Nobili, Flavio, and for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders

Published
2018
Full Text
View/download PDF

32. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia

Author

Nestor, Peter J., Altomare, Daniele, Festari, Cristina, Drzezga, Alexander, Rivolta, Jasmine, Walker, Zuzana, Bouwman, Femke, Orini, Stefania, Law, Ian, Agosta, Federica, Arbizu, Javier, Boccardi, Marina, Nobili, Flavio, Frisoni, Giovanni Battista, and for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders

Published
2018
Full Text
View/download PDF

34. Sporadic Creutzfeldt–Jakob disease is associated with reorganization of metabolic connectivity in a pathological brain network

Author

Rus, Tomaž, primary, Mlakar, Jernej, additional, Ležaić, Luka, additional, Vo, An, additional, Nguyen, Nha, additional, Tang, Chris, additional, Fiorini, Michele, additional, Prieto, Elena, additional, Marti‐Andres, Gloria, additional, Arbizu, Javier, additional, Eidelberg, David, additional, and Trošt, Maja, additional

Published
2023
Full Text
View/download PDF

36. Radioembolization: Concepts and Procedures

Author

Arbizu, Javier, Bilbao, José I., Garrastachu, Puy, Rodriguez-Fraile, Macarena, Domínguez-Prado, Inés, Iñarrairaegui, Mercedes, Sangro, Bruno, Brady, Luther W., Series editor, Lu, Jiade J., Series editor, Nieder, Carsten, Series editor, and Baum, Richard P., editor

Published
2014
Full Text
View/download PDF

38. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study.

Author

Mitjavila, Mercedes, Jimenez-Fonseca, Paula, Belló, Pilar, Pubul, Virginia, Percovich, Juan Carlos, Garcia-Burillo, Amparo, Hernando, Jorge, Arbizu, Javier, Rodeño, Emilia, Estorch, Montserrat, Llana, Belén, Castellón, Maribel, García-Cañamaque, Lina, Gajate, Pablo, Riesco, Maria Carmen, Miguel, Maria Begoña, Balaguer-Muñoz, David, Custodio, Ana, Cano, Juana María, and Repetto, Alexandra

Subjects
NEUROENDOCRINE tumors, SOMATOSTATIN receptors, PEPTIDE receptors, PROGRESSION-free survival, SURVIVAL rate, HOLMIUM, LUTETIUM compounds
Abstract

Background: Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [177Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables. Advanced NENs overexpressing somatostatin receptors (SSTRs) on functional imaging, of any grade or location, treated at 24 centers were enrolled. The protocol consisted of four cycles of 177Lu-DOTATATE 7.4 GBq iv every 8 weeks (NCT04949282). Results: The sample comprised 522 subjects with pancreatic (35%), midgut (28%), bronchopulmonary (11%), pheochromocytoma/ paraganglioma (PPGL) (6%), other gastroenteropancreatic (GEP) (11%), and other non-gastroenteropancreatic (NGEP) (9%) NENs. The best RECIST 1.1 responses were complete response, 0.7%; partial response, 33.2%; stable disease, 52.1%; and tumor progression, 14%, with activity conditioned by the tumor subtype, but with benefit in all strata. Median progression-free survival (PFS) was 31.3 months (95% CI, 25.7–not reached [NR]) in midgut, 30.6 months (14.4-NR) in PPGL, 24.3 months (18.0-NR) in other GEP, 20.5 months (11.8-NR) in other NGEP, 19.8 months (16.8–28.1) in pancreatic, and 17.6 months (14.4–33.1) in bronchopulmonary NENs. [177Lu]Lu-DOTATATE exhibited scant severe toxicity. Conclusion: This study confirms the efficacy and safety of [177Lu]Lu-DOTATATE in a wide range of SSTR-expressing NENs, regardless of location, with clinical benefit and superimposable survival outcomes between pNENs and other GEP and NGEP tumor subtypes different from midgut NENs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis

Author

Morbelli, Silvia, Arbizu, Javier, Booij, Jan, Chen, Ming-Kai, Chetelat, Gael, Cross, Donna J., Djekidel, Mehdi, Drzezga, Alexander, Ekmekcioglu, Ozgul, Garibotto, Valentina, Hesse, Swen, Ishii, Kazunari, Saraf, Lida Jafari, Lammertsma, Adriaan A., Law, Ian, Mathews, Dana, Minoshima, Satoshi, Mosci, Karina, Pagani, Marco, Pappata, Sabina, Silverman, Daniel Hillel, Signore, Alberto, Van De Giessen, Elsmarieke, Villemagne, Victor, Barthel, Henryk, and on behalf of the European Association of Nuclear Medicine (EANM) and of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Published
2017
Full Text
View/download PDF

41. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

Author

Garcia-Carbonero, Rocio, Garcia-Figueiras, Roberto, Carmona-Bayonas, Alberto, Sevilla, Isabel, Teule, Alex, Quindos, Maria, Grande, Enrique, Capdevila, Jaume, Aller, Javier, Arbizu, Javier, Jimenez-Fonseca, Paula, and on behalf of the Spanish Cooperative Group of Neuroendocrine Tumors (GETNE)

Published
2015
Full Text
View/download PDF

44. Proven validity and management impact of amyloid imaging in Alzheimer’s disease—repetita juvant

Author

Barthel, Henryk, Arbizu, Javier, Ekmekcioglu, Ozgul, Guedj, Eric, Law, Ian, Penuelas, Ivan, Semah, Franck, Traub-Weidinger, Tatjana, van de Giessen, Elsmarieke, Varrone, Andrea, Drzezga, Alexander, Garibotto, Valentina, Lammertsma, Adriaan A, Morbelli, Silvia, Committee, EANM Neuroimaging, Albert, Nathalie, Boellaard, Ronald, Cecchin, Diego, Radiology and Nuclear Medicine, ANS - Neurodegeneration, Amsterdam Neuroscience - Neurodegeneration, Radiology and nuclear medicine, and AMS - Tissue Function & Regeneration

Subjects
Amyloid, Amyloid beta-Peptides, Humans, Alzheimer Disease, business.industry, MEDLINE, General Medicine, Disease, Bioinformatics, medicine.disease, ddc:616.0757, mental disorders, Medicine, Radiology, Nuclear Medicine and imaging, ddc:610, Alzheimer's disease, business
Abstract

The Editorial “Suboptimal Validity of Amyloid Imaging-Based Diagnosis and Management of Alzheimer’s Disease: Why It Is Time to Abandon the Approach” which appeared online ahead of print on October 31, 2019, in the EJNMMI [1] has come to our attention. From our point of view, the topic of amyloid imaging is discussed in a biased and opinionated form in this Editorial. Some facts generally accepted by imaging experts and neuropathologists are questioned or neglected, which may leave the reader with a misleading impression that does not correspond with the current state of knowledge. The EANM Neuroimaging Committee, thus, feels the need to correct this impression in order to allow the reader to differentiate between commonly accepted scientific facts versus individual opinions and matters still unresolved, regarding the topic discussed. For space reasons, we will discuss here only the issues with the greatest risk for misleading interpretation.

Published
2020

45. Brain Imaging

Author

van de Giessen, Elsmarieke, additional, Morbelli, Silvia, additional, Payoux, Pierre, additional, Socan, Aljaz, additional, Hackett, Elizabeth C., additional, Testanera, Giorgio, additional, Pepe, Giovanna, additional, Lucena, Filipa, additional, Sousa, Eva, additional, Vaz, Tânia F., additional, Law, Ian, additional, Garibotto, Valentina, additional, Pagani, Marco, additional, Delgado-Bolton, Roberto, additional, Calapaquí-Terán, Adriana K., additional, Arbizu, Javier, additional, Werner, Peter, additional, Boehm, Torsten, additional, Tiepolt, Solveig, additional, Barthel, Henryk, additional, Hoffmann, Karl T., additional, Sabri, Osama, additional, Grmek, Marko, additional, and Peștean, Claudiu, additional

Published
2015
Full Text
View/download PDF

49. Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis

Author

Morbelli, Silvia, Arbizu, Javier, Booij, Jan, Chen, Ming-Kai, Chetelat, Gael, Cross, Donna J., Djekidel, Mehdi, Drzezga, Alexander, Ekmekcioglu, Ozgul, Garibotto, Valentina, Hesse, Swen, Ishii, Kazunari, Jafari, Lida, Lammertsma, Adriaan A., Law, Ian, Mathews, Dana, Minoshima, Satoshi, Mosci, Karina, Pagani, Marco, Pappata, Sabina, Silverman, Daniel Hillel, Signore, Alberto, Van De Giessen, Elsmarieke, Villemagne, Victor, Barthel, Henryk, and on behalf of the European Association of Nuclear Medicine (EANM) and of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results